11/19
09:04 am
vrdn
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
Low
Report
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
11/14
08:15 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at HC Wainwright from $27.00 to $34.00. They now have a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at HC Wainwright from $27.00 to $34.00. They now have a "buy" rating on the stock.
11/14
05:32 am
vrdn
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/13
08:06 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
11/12
07:00 am
vrdn
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
High
Report
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
11/5
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/28
08:25 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
10/23
04:03 pm
vrdn
Viridian Therapeutics' Superior Prospects Make It A Buy [Seeking Alpha]
Low
Report
Viridian Therapeutics' Superior Prospects Make It A Buy [Seeking Alpha]
10/15
11:54 am
vrdn
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - Global Forecast to 2030 [Yahoo! Finance]
Low
Report
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - Global Forecast to 2030 [Yahoo! Finance]
9/26
01:08 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at BTIG Research from $56.00 to $61.00. They now have a "buy" rating on the stock.
Neutral
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at BTIG Research from $56.00 to $61.00. They now have a "buy" rating on the stock.
9/19
10:55 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
9/13
10:09 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $44.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $44.00. They now have an "outperform" rating on the stock.
9/12
12:14 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $25.00 to $31.00. They now have a "buy" rating on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $25.00 to $31.00. They now have a "buy" rating on the stock.
9/11
11:34 pm
vrdn
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock [Yahoo! Finance]
9/11
11:25 pm
vrdn
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
Medium
Report
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
9/11
08:02 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Needham & Company LLC from $30.00 to $38.00. They now have a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Needham & Company LLC from $30.00 to $38.00. They now have a "buy" rating on the stock.
9/11
06:55 am
vrdn
Viridian Therapeutics' stock jumps after Phase III trial met all endpoints [Yahoo! Finance]
Medium
Report
Viridian Therapeutics' stock jumps after Phase III trial met all endpoints [Yahoo! Finance]
9/10
04:01 pm
vrdn
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
Medium
Report
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
9/10
02:06 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
9/10
12:09 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at BTIG Research from $46.00 to $56.00. They now have a "buy" rating on the stock.
High
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at BTIG Research from $46.00 to $56.00. They now have a "buy" rating on the stock.
9/10
07:00 am
vrdn
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
High
Report
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
9/9
04:09 pm
vrdn
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 [Yahoo! Finance]
High
Report
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 [Yahoo! Finance]
9/9
04:01 pm
vrdn
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
High
Report
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
9/5
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/30
12:16 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.